Isoindoline Compounds Targeting Integrase-LEDGF Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatment regimens, such as HAART, face challenges with drug resistance, complex therapy protocols, and limited options for salvage therapy due to the rapid emergence of multidrug-resistant HIV variants, necessitating the development of new drugs with different targets and mechanisms of action.
Innovation Solution
Development of substituted isoindoline compounds that inhibit HIV replication by targeting the protein-protein interaction between HIV integrase and LEDGF, offering a new therapeutic approach for treating HIV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HAART therapy combines multiple drugs targeting reverse transcriptase and protease, then viral replication is suppressed and patient survival increases, but drug resistance emerges due to mutation of enzyme targets
Solution Approach 1:
The patent introduces LEDGF as an intermediary target - rather than directly inhibiting viral enzymes, the compound inhibits the protein-protein interaction between integrase and LEDGF. This intermediary approach allows suppression of viral replication through a different mechanism that bypasses resistance mutations in traditional enzyme targets.
Solution Approach 2:
The invention changes the target parameter from viral enzymes (reverse transcriptase, protease) to the integrase-LEDGF protein-protein interaction interface. This parameter change enables a new mechanism of action that is effective against multidrug-resistant strains while maintaining reliable viral replication suppression.
2Adaptability or versatility
If salvage therapy uses different combinations of drugs from the same mechanistic class, then treatment options are available for resistant isolates, but cross-resistance limits the options
Solution Approach 1:
Instead of combining multiple drugs that target the same viral enzymes (which leads to cross-resistance), the patent inverts the approach by targeting the host cellular protein LEDGF that interacts with viral integrase. This inverted strategy provides a completely new mechanistic class with no cross-resistance to existing antiretroviral drugs.
Solution Approach 2:
The isoindoline compound serves as a universal inhibitor of the integrase-LEDGF interaction, providing a multi-functional approach that works across different HIV strains including multidrug-resistant isolates, thereby expanding treatment options without being limited by cross-resistance.
3Adaptability or versatility
If new drugs with different targets and mechanisms are developed, then drug resistance is overcome and treatment versatility improves, but therapy complexity increases
Solution Approach 1:
The patent extracts the core functional element (LEDGF) from the complex viral replication machinery and targets it specifically. By focusing on this single host protein interaction rather than combining multiple viral enzyme inhibitors, the therapy achieves mechanism diversity while simplifying the treatment protocol to a single agent.
Data Source
AI summary
Compounds of Formula I are disclosed and methods of treating viral infections with compositions comprising such compounds (Formula I)